 NEW YORK, March 24, 2021 PRNewswire -- Actinium Pharmaceuticals, Inc. NYSE AMERICAN: ATNM Actinium or the Company today announced that its collaborator, Memorial Sloan Kettering Cancer Center MSK, has commenced patient enrollment in the Phase 1 study evaluating Iomab-ACT for targeted conditioning prior to treatment with MSKs CD19 targeted CAR T-cell 19-28z. Iomab-ACT is a low dose version of Actiniums Phase 3 drug candidate Iomab-B, a CD45 targeting antibody radiation conjugate ARC. 